Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

By Yamada Yasuhide  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1690-1696

Springer Publishing Company

Access to resources Recommend Favorite

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

By Kang Yoon-Koo   Muro Kei   Ryu Min-Hee   Yasui Hirofumi   Nishina Tomohiro   Ryoo Baek-Yeol   Kamiya Yukimasa   Akinaga Shiro   Boku Narikazu  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 355-361

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions

By Lin Nancy   Parker Leroy   Come Steven   Burstein Harold   Haldoupis Margaret   Ryabin Nicole   Gelman Rebecca   Winer Eric   Shulman Lawrence  

Investigational New Drugs, Vol. 25, Iss. 4, 2007-08 ,pp. : 369-375

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of the efficacy and safety of oral GD0039 in patients with locally advanced or metastatic renal cell carcinoma

By Shaheen Philip   Stadler Walter   Elson Paul   Knox Jennifer   Winquist Eric   Bukowski Ronald  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 577-581

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98)

By Bjarnason Georg   Charpentier Danielle   Wong Ralph   Goel Rakesh   Douglas Lynn   Walsh Wendy   Matthews Sarah   Dent Susan   Seymour Lesley  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 51-56

Springer Publishing Company

Access to resources Recommend Favorite